Serum ADAM17 levels pre-antiviral therapy correlate with HIV patient immune reconstitution

Background: The relationship between tumour necrosis factor (TNF) levels and disease progression is well-established. However, the impact of changes in the level of TNF hydrolase (A-disintegrin and metalloenzyme 17; ADAM17) in HIV patients remains to be fully elucidated. Methods: Between March 1 and...

Full description

Saved in:
Bibliographic Details
Main Authors: Ying Lin, Ming Chen, Xuelian Zhu, xiaoya cui, Suyu Sun, Xingzhong Hu
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024167655
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850108798651334656
author Ying Lin
Ming Chen
Xuelian Zhu
xiaoya cui
Suyu Sun
Xingzhong Hu
author_facet Ying Lin
Ming Chen
Xuelian Zhu
xiaoya cui
Suyu Sun
Xingzhong Hu
author_sort Ying Lin
collection DOAJ
description Background: The relationship between tumour necrosis factor (TNF) levels and disease progression is well-established. However, the impact of changes in the level of TNF hydrolase (A-disintegrin and metalloenzyme 17; ADAM17) in HIV patients remains to be fully elucidated. Methods: Between March 1 and December 31, 2017, data were collected from 64 HIV-positive individuals in Wenzhou. Based on their history of antiviral treatment at the time of enrollment, these patients were categorized into two cohorts: an antiviral-treated group and an untreated HIV group. Then, the serum ADAM17 levels of each group were measured and analysed. Results: In comparison to the antiviral-treated group and the control group, the untreated HIV group exhibited a significantly elevated serum ADAM17 level (p < 0.001). A significant negative correlation was observed between serum ADAM17 levels and CD4+ T cell counts in the untreated HIV group (r = −0.486, p = 0.001). ROC curve analysis revealed that the pre-treatment serum ADAM17 level in the untreated HIV group had moderate diagnostic accuracy for the AIDS stage (area under the curve: 0.703, p = 0.028). Additionally, serum ADAM17 levels were positively correlated with ADAM17 expression on the surface of leukocytes (r = 0.367, p = 0.018). Conclusion: Serum ADAM17 levels are significantly elevated in HIV patients and are correlated with disease progression and immune reconstitution.
format Article
id doaj-art-851c2ad3a3eb482580cca2b9807bccd2
institution OA Journals
issn 2405-8440
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Heliyon
spelling doaj-art-851c2ad3a3eb482580cca2b9807bccd22025-08-20T02:38:15ZengElsevierHeliyon2405-84402024-12-011023e4073410.1016/j.heliyon.2024.e40734Serum ADAM17 levels pre-antiviral therapy correlate with HIV patient immune reconstitutionYing Lin0Ming Chen1Xuelian Zhu2 xiaoya cui3Suyu Sun4Xingzhong Hu5Department of Clinical Laboratory Medicine, Wenzhou Central Hospital, Dingli Clinical School of Wenzhou Medical University, Wenzhou, 325000, ChinaThe Third Affiliated Hospital of Wenzhou Medical University, Ruian 325200, Zhejiang, ChinaDingli Clinical School of Wenzhou Medical University, Wenzhou, 325000, ChinaDepartment of Infectious Diseases, Wenzhou Central Hospital, Dingli Clinical School of Wenzhou Medical University, Wenzhou, 325000, ChinaGynaecology and obstetrics, Wenzhou Central Hospital, Dingli Clinical School of Wenzhou Medical University, Wenzhou, 325000, China; Corresponding author.Department of Clinical Laboratory Medicine, Wenzhou Central Hospital, Dingli Clinical School of Wenzhou Medical University, Wenzhou, 325000, China; Corresponding author.Background: The relationship between tumour necrosis factor (TNF) levels and disease progression is well-established. However, the impact of changes in the level of TNF hydrolase (A-disintegrin and metalloenzyme 17; ADAM17) in HIV patients remains to be fully elucidated. Methods: Between March 1 and December 31, 2017, data were collected from 64 HIV-positive individuals in Wenzhou. Based on their history of antiviral treatment at the time of enrollment, these patients were categorized into two cohorts: an antiviral-treated group and an untreated HIV group. Then, the serum ADAM17 levels of each group were measured and analysed. Results: In comparison to the antiviral-treated group and the control group, the untreated HIV group exhibited a significantly elevated serum ADAM17 level (p < 0.001). A significant negative correlation was observed between serum ADAM17 levels and CD4+ T cell counts in the untreated HIV group (r = −0.486, p = 0.001). ROC curve analysis revealed that the pre-treatment serum ADAM17 level in the untreated HIV group had moderate diagnostic accuracy for the AIDS stage (area under the curve: 0.703, p = 0.028). Additionally, serum ADAM17 levels were positively correlated with ADAM17 expression on the surface of leukocytes (r = 0.367, p = 0.018). Conclusion: Serum ADAM17 levels are significantly elevated in HIV patients and are correlated with disease progression and immune reconstitution.http://www.sciencedirect.com/science/article/pii/S2405844024167655ADAM17HIVCD4+ T cells
spellingShingle Ying Lin
Ming Chen
Xuelian Zhu
xiaoya cui
Suyu Sun
Xingzhong Hu
Serum ADAM17 levels pre-antiviral therapy correlate with HIV patient immune reconstitution
Heliyon
ADAM17
HIV
CD4+ T cells
title Serum ADAM17 levels pre-antiviral therapy correlate with HIV patient immune reconstitution
title_full Serum ADAM17 levels pre-antiviral therapy correlate with HIV patient immune reconstitution
title_fullStr Serum ADAM17 levels pre-antiviral therapy correlate with HIV patient immune reconstitution
title_full_unstemmed Serum ADAM17 levels pre-antiviral therapy correlate with HIV patient immune reconstitution
title_short Serum ADAM17 levels pre-antiviral therapy correlate with HIV patient immune reconstitution
title_sort serum adam17 levels pre antiviral therapy correlate with hiv patient immune reconstitution
topic ADAM17
HIV
CD4+ T cells
url http://www.sciencedirect.com/science/article/pii/S2405844024167655
work_keys_str_mv AT yinglin serumadam17levelspreantiviraltherapycorrelatewithhivpatientimmunereconstitution
AT mingchen serumadam17levelspreantiviraltherapycorrelatewithhivpatientimmunereconstitution
AT xuelianzhu serumadam17levelspreantiviraltherapycorrelatewithhivpatientimmunereconstitution
AT xiaoyacui serumadam17levelspreantiviraltherapycorrelatewithhivpatientimmunereconstitution
AT suyusun serumadam17levelspreantiviraltherapycorrelatewithhivpatientimmunereconstitution
AT xingzhonghu serumadam17levelspreantiviraltherapycorrelatewithhivpatientimmunereconstitution